RU2011100127A - Соединение, содержащее пептид, для лечения симптомов болезни паркинсона - Google Patents

Соединение, содержащее пептид, для лечения симптомов болезни паркинсона Download PDF

Info

Publication number
RU2011100127A
RU2011100127A RU2011100127/15A RU2011100127A RU2011100127A RU 2011100127 A RU2011100127 A RU 2011100127A RU 2011100127/15 A RU2011100127/15 A RU 2011100127/15A RU 2011100127 A RU2011100127 A RU 2011100127A RU 2011100127 A RU2011100127 A RU 2011100127A
Authority
RU
Russia
Prior art keywords
amino acid
compound according
tyrosine
arginine
leucine
Prior art date
Application number
RU2011100127/15A
Other languages
English (en)
Russian (ru)
Inventor
Маркус МАНДЛЕР (AT)
Маркус МАНДЛЕР
Франк МАТТНЕР (AT)
Франк МАТТНЕР
Вальтер ШМИДТ (AT)
Вальтер Шмидт
Original Assignee
Аффирис Аг (At)
Аффирис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0095108A external-priority patent/AT506819B1/de
Priority claimed from AT0095208A external-priority patent/AT506820B1/de
Application filed by Аффирис Аг (At), Аффирис Аг filed Critical Аффирис Аг (At)
Publication of RU2011100127A publication Critical patent/RU2011100127A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2011100127/15A 2008-06-12 2009-06-12 Соединение, содержащее пептид, для лечения симптомов болезни паркинсона RU2011100127A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT0095108A AT506819B1 (de) 2008-06-12 2008-06-12 Vakzin zur behandlung von alzheimer-krankheit
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
ATA951/2008 2008-06-12
ATA952/2008 2008-06-12

Publications (1)

Publication Number Publication Date
RU2011100127A true RU2011100127A (ru) 2012-07-20

Family

ID=41417160

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011100127/15A RU2011100127A (ru) 2008-06-12 2009-06-12 Соединение, содержащее пептид, для лечения симптомов болезни паркинсона

Country Status (12)

Country Link
US (2) US20110092436A1 (https=)
EP (1) EP2310032A2 (https=)
JP (1) JP2011522842A (https=)
KR (1) KR20110036809A (https=)
CN (1) CN102123726A (https=)
AU (1) AU2009257170B2 (https=)
BR (1) BRPI0915134A2 (https=)
CA (1) CA2723995A1 (https=)
IL (1) IL209896A0 (https=)
MX (1) MX2010013647A (https=)
RU (1) RU2011100127A (https=)
WO (1) WO2009149487A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
SI2579042T1 (sl) 2011-10-04 2014-09-30 Affiris Ag Postopek za detektiranje Ass-specifičnih protiteles v biološkem vzorcu
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015185602A1 (en) * 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
WO2016131420A1 (zh) * 2015-02-17 2016-08-25 上海交通大学医学院附属上海儿童医学中心 急性淋巴细胞白血病耐药复发相关突变基因及其应用
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN106632607A (zh) * 2016-12-29 2017-05-10 华东理工大学 靶向survivin纳米抗体及其制备方法和应用
TWI705975B (zh) 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
CN110156887B (zh) * 2018-02-12 2023-01-13 中国人民解放军军事科学院军事医学研究院 人vasn蛋白抗原表位、抗原模拟表位及其用途
CN108676071B (zh) * 2018-05-24 2021-05-14 华南理工大学 一种抗Aβ蛋白聚集的七肽及其应用与编码该合成多肽的基因
CN108676072B (zh) * 2018-05-24 2021-05-14 华南理工大学 一种具有抗Aβ42蛋白聚集功能的多肽及其应用与编码该多肽的基因
CN111040020B (zh) * 2018-12-28 2022-04-12 中国人民解放军军事科学院军事医学研究院 一种烯烃硫醚类订书肽及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
CZ20022748A3 (cs) * 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20040265849A1 (en) * 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
US20050176030A1 (en) * 2003-10-28 2005-08-11 Li Gan Regulated nucleic acids in pathogenesis of Alzheimer's Disease
JP2005330231A (ja) * 2004-05-20 2005-12-02 Otsuka Pharmaceut Co Ltd 医薬組成物
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
JP2011511841A (ja) * 2008-02-12 2011-04-14 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤

Also Published As

Publication number Publication date
CA2723995A1 (en) 2009-12-17
EP2310032A2 (en) 2011-04-20
KR20110036809A (ko) 2011-04-11
BRPI0915134A2 (pt) 2016-02-16
CN102123726A (zh) 2011-07-13
US20110092436A1 (en) 2011-04-21
MX2010013647A (es) 2011-04-05
WO2009149487A3 (en) 2010-07-29
JP2011522842A (ja) 2011-08-04
IL209896A0 (en) 2011-02-28
AU2009257170B2 (en) 2014-06-12
US20130287807A1 (en) 2013-10-31
WO2009149487A2 (en) 2009-12-17
AU2009257170A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
RU2011100127A (ru) Соединение, содержащее пептид, для лечения симптомов болезни паркинсона
JP2011522842A5 (https=)
RU2011100125A (ru) Соединения для лечения амилоидозов
RU2011100126A (ru) Применение мимотопов для лечения бетта-амилоидозов
CN1241942C (zh) 使用胰岛素的肽类似物治疗糖尿病的方法
US20200140488A1 (en) Alzheimer's disease treatment method
JP2011529084A5 (https=)
RU2012110582A (ru) Применение мимеотопов альфа-синуклеиновых эпитопов для лечения заболеваний, связанных с тельцами леви
RU2010110567A (ru) Пептид foxm1 и включающее его медицинское средство
EA201070812A1 (ru) Лечение и профилактика амилоидоза
JP2003503312A5 (https=)
RU2010110564A (ru) Пептид cdca1 и включающее его фармацевтическое средство
US9884091B2 (en) Treatment of neurological diseases
RU2010110545A (ru) Cdh3-пептид и включающее его лекарственное средство
RU2014114506A (ru) Вакцина
RU2011153023A (ru) Конъюгат амилоидного пептида и композиция на его основе для лечения или предупреждения заболевания, ассоциированного с отложением амилоидных белков
WO2019195712A2 (en) Compstatin analogs with increased solubility and improved pharmacokinetic properties
RU2010126154A (ru) Эпитопные пептиды stat3
CN105121463B (zh) 肽
JP2020511425A5 (https=)
RU2007115411A (ru) Пептиды hsp60 и их apl-производные и фармацевтические композиции
RU2012100241A (ru) Лечение хориоидальной неоваскуляризации с помощью вакцин
AU2020347906B2 (en) Proinsulin peptides for Type 1 Diabetes
JP2020530846A5 (https=)
ES2541754T3 (es) Vacuna

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150115